The benefit of artificial oocyte activation is dependent on the fertilization rate in a previous treatment cycle
|
|
- Jacob Waters
- 6 years ago
- Views:
Transcription
1 Reproductive BioMedicine Online (2012) 24, ARTICLE The benefit of artificial oocyte activation is dependent on the fertilization rate in a previous treatment cycle Markus Montag a,b, *, Maria Köster b, Katrin van der Ven b, Ulrike Bohlen b, Hans van der Ven b a Department of Gynecological Endocrinology and Fertility Disorders, University of Heidelberg, Voßstr. 9, Heidelberg, Germany; b Department of Gynecological Endocrinology and Reproductive Medicine, University of Bonn, Bonn, Germany * Corresponding author. address: markus.montag@med.uni-heidelberg.de (M Montag). Prof Markus Montag obtained his PhD at the German Cancer Research Centre and worked at NUH, Singapore with Prof SC Ng. Returning from Singapore, he was laboratory director in a private IVF unit before becoming Director of the Reproductive Biology Laboratory at the University Clinics of Bonn in 1995 and Associate Professor for Experimental Reproductive Medicine in In 2011 he became Head of the IVF Laboratory at the University Clinics of Heidelberg. He is actively involved in counselling IVF centres and educating young people in the field worldwide. His research areas include the use of lasers, ovarian tissue cryobanking, oocyte activation, polarization microscopy and polar body biopsy. Abstract Following intracytoplasmic sperm injection (ICSI), some patients present low or zero fertilization rates. Artificial oocyte activation has been proposed as a suitable means to overcome this problem. This study applied artificial oocyte activation in patient cohorts with a history of no fertilization (0%, group 1), fertilization between 1 and 29% (group 2) or fertilization between 30 and 50% (group 3) in initial ICSI cycles. In the following treatment cycles, oocytes were activated after ICSI using calcium ionophore. Fertilization, pregnancy and take-home baby rates were compared with the previous cycle without activation. In group 1, fertilization rate was 41.6%, embryos for transfer were available in 82.1% of cycles, giving a clinical pregnancy rate of 18.8% and take-home baby rate of 12.8%. In group 2, despite a lower transfer rate (87.9% versus 100%, P < 0.05), there were higher fertilization and clinical pregnancy rates (44.4% versus 19.3% and 31.4% versus 12.8%, respectively, P < 0.05) and take-home baby rate was 24.1% versus 12.8%. In group 3, fertilization rates differed (56.1% versus 36.8%; P < 0.001) but all other parameters were similar. Artificial oocyte activation has great potential especially in patients showing compromised fertilization rates below 30% after standard ICSI. RBMOnline ª 2012, Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved. KEYWORDS: activation failure, fertilization, ionophore, oocyte, spermatozoa /$ - see front matter ª 2012, Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved. doi: /j.rbmo
2 522 M Montag et al. Introduction The introduction of intracytoplasmic sperm injection (ICSI) has made it possible to overcome most problems associated with male factor infertility, namely low sperm count and reduced motility (Palermo et al., 1992, 1996). Since then, ICSI has proven to be very efficient following fertilization failure in a normal IVF cycle and to yield constantly high fertilization rates of 70 80% on average. However, although failed fertilization after ICSI is a rare event (Liu et al., 1995), it still exists. Moreover, 0 30% fertilization rates can consistently be observed in repeated ICSI cycles for some patients. The incidence of fertilization problems after ICSI raises the question of the underlying aetiology, especially with regard to the role of the spermatozoon for achieving successful fertilization. One of the initial events of the fertilization cascade is the activation of the oocyte by a sperm-derived oocyte activation factor. The exact nature of this sperm factor was among the focus of basic research since the early 1990s (Kline and Kline, 1992; Swann and Ozil, 1994). It finally resulted in the identification of a novel sperm-specific phospholipase PLC, PLCf, which is considered to be responsible for mammalian oocyte activation (Saunders et al., 2002; Swann et al., 2004). To date, two studies have shown that fertilization failure in infertile men can be linked to aberrant forms or reduced amounts or even absence of PLCf (Heytens et al., 2009; Yoon et al., 2008). The majority of patients in these studies were diagnosed with round-headed spermatozoa or globozoospermia, a sperm defect which is associated with failed oocyte activation after ICSI (Battaglia et al., 1997; Rybouchkin et al., 1996). One successful ICSI treatment option for men with globozoospermia is artificial oocyte activation using calcium ionophore (Rybouchkin et al., 1997; Taylor et al., 2010). The potential of calcium ionophore to support oocyte activation and yield high fertilization rates was shown at the beginning of the era of ICSI (Tesarik et al., 1995). However, artificial activation was never routinely applied after ICSI but instead was restricted to those patients showing fertilization failure after ICSI, independently of the sperm diagnosis (Eldar-Geva et al., 2003; Heindryckx et al., 2008, 2005). In 2003, this study centre started applying artificial oocyte activation in cases with 0%, 1 29% and 30 50% fertilization after ICSI. Here is presented a retrospective analysis of the success rates in these cases by comparing the outcomes of the initial cycles with the following cycles that applied artificial oocyte activation. Materials and methods Patients, ovarian stimulation and oocyte retrieval In the study period between 2003 and 2009, patients with 0%, 1 29% or 30 50% fertilization in a previous ICSI cycle were considered for this study. Ethical approval was not required as the study was considered as a therapeutic treatment approach based on published reports (Eldar-Geva et al., 2003; Rybouchkin et al., 1997; Tesarik et al., 1995). Cases with surgically retrieved spermatozoa from the testis or the epididymis were excluded. Patients gave informed consent for artificial oocyte activation. Ovarian stimulation and oocyte retrieval followed standard protocols using either long or short stimulation with agonist or antagonist. Ovulation was triggered by administration of 250 lg human chorionic gonadotrophin (HCG) and oocyte retrieval was scheduled h later. ICSI, culture, embryo transfer and pregnancy Cumulus oocyte complexes were isolated and rinsed in HEPES-buffered medium (gamete medium; Cook, Brisbane, Australia) followed by fertilization medium (Cook) and incubated in fertilization medium in humidified air at 6% CO 2 in a 4-well dish. After 2 3 h, oocytes were denuded with hyaluronidase (Cook) and incubated for another 1 2 h prior to ICSI in cleavage medium (Cook). ICSI was performed at an inverted microscope (DMIRB; Leica, Wetzlar, Germany) equipped with a heated table and micromanipulators (Narishige, Tokyo, Japan). Spermatozoa were prepared by a modified mini-swim-up technique (Montag et al., 1997) and placed into polyvinylpyrrolidone solution (ICSI medium; Cook) in a standard plastic dish. In the same dish, oocytes were placed in droplets of gamete medium and were injected using appropriate micro-capillaries (Cook) with a standard ICSI injection technique, as described (Montag et al., 1997). The presence of pronuclei was checked h after ICSI. Two to three 2-pronuclear (PN) oocytes were chosen for further culture and transfer, and surplus 2PN oocytes were cryopreserved. 2PN oocytes for transfer and culture were placed into a new dish and were cultured for another 1 2 days. Embryo transfer was performed on day 3 as described (Montag et al., 2002). A first bhcg test was performed 14 days after oocyte retrieval and if positive the test was repeated 2 days later. The presence and number of fetal sacs was confirmed by ultrasound scan 14 days later and fetal heart beat was investigated another 14 days later. The implantation rate was calculated by the number of fetal sacs divided by the number of embryos transferred. Only pregnancies with a proven implantation were classified as clinical pregnancies. Pregnant patients were asked to submit data on birthweight and the health of the children born. Artificial oocyte activation Oocyte activation was performed as described (Tesarik et al., 1995) with some modifications. Immediately after ICSI, oocytes were incubated for 15 min in a 50-ll droplet of activation solution (10 lmol/l calcium ionophore A23187 in culture medium; cleavage medium; Cook) covered by mineral oil (Cook). After exposure to the activation solution, oocytes were thoroughly washed in culture medium and incubated under standard conditions in 6% CO 2,5%O 2 and 89% N 2 in humidified atmosphere (Minc; Cook). Statistics Statistical analysis used GrapPadPrism 5 and ANOVA or chi-squares tests whenever appropriate. P-values <0.05 were considered significant.
3 Artificial oocyte activation 523 Results Artificial activation in patients with 0% initial fertilization rate A total of 27 patients, who presented with absent fertilization in 31 standard ICSI cycles, returned in the study period for at least one more ICSI cycle in which artificial oocyte activation was performed. When the characteristic features of the 31 cycles without activation to the 39 cycles with artificial activation were compared, there was a non-significant increase in the mean female age (36.1 years versus 37.8 years; Table 1). The number of oocytes retrieved, as well as the number of mature oocytes for ICSI, was different (5.4 and 3.7 versus 7.4 and 5.9, P < 0.05 and P < 0.001, respectively). However, following artificial oocyte activation, a fertilization rate of 41.6% was achieved, which resulted in 82.1% embryo transfers with a mean number of 1.46 embryos transferred. The implantation rate was 12.3%, giving rise to a positive bhcg rate, clinical pregnancy rate and take-home baby rate per transfer cycle of 25.0%, 18.8% and 15.6%, respectively. The birthweight of the children born was 3196 ± 340 g and all children born were healthy and without any malformations. Artificial activation in patients with 1 29% initial fertilization rate A total of 38 patients presented with a fertilization rate of 1 29% in 47 standard ICSI cycles and returned in the study period for at least one more ICSI cycle, in which artificial oocyte activation was performed. When the characteristic features of the 47 cycles without activation were compared with the 58 cycles with artificial activation, there was a significant increase in the mean female age (33.3 years to 35.3 years, P < 0.05; Table 2). The number of oocytes retrieved, as well as the number of mature oocytes for ICSI, was not different (8.0 and 6.2 versus 7.8 and 6.1, respectively). In the cycles with artificial oocyte activation, the fertilization rates were higher (19.3% versus 44.4%, P < 0.001). However, there was a lower rate of embryo transfer cycles (100% versus 87.9%, P < 0.05), because in six patients who had only one oocyte fertilized in the previous cycles without activation, no fertilization occurred in seven treatment cycles with activation. A comparable mean number of embryos were transferred after activation (1.48 versus 1.57). The positive bhcg rate as well as the clinical pregnancy rate was significantly higher with artificial oocyte activation than without (14.9% and 12.8% versus 37.3% and 31.4%, respectively, P < 0.05). There was a non-significant trend towards higher implantation rates in artificial activation cycles (8.6% versus 17.6%). There was also no significant difference in the abortion rate (0.0% versus 12.5%) and the take-home baby rate per embryo transfer (12.8% versus 27.5%). With artificial oocyte activation the take-home baby rate per ICSI cycle was higher (12.8% versus 24.1%) although the difference did not reach statistical significance. The birthweight of the children born was not different (3445 ± 399 g with activation versus 3952 ± 530 g without artificial activation). All children born were healthy and without any malformations. Artificial activation in patients with 30 50% initial fertilization rate In the same time period, a total of 24 patients presented with 30 50% fertilization rate in 25 standard ICSI cycles and consented to a subsequent treatment with artificial oocyte activation in another 32 ICSI cycles. The mean female age was 34.0 years in the standard cycles and 35.4 years in the cycles with activation (Table 3). The mean number of oocytes retrieved and injected was not different between standard and artificial activation cycles (9.2 and 7.0 versus 8.9 and 6.7, respectively). Fertilization rates Table 1 Results of artificial oocyte activation in patients with 0% fertilization rates in an initial cycle (group 1). Standard ICSI Artificial oocyte activation P-value Patients (n) Female age (years) 36.1 ± ± 3.4 NS ICSI cycles (n) Oocytes retrieved 5.4 ± ± 3.8 <0.05 Oocytes injected 3.7 ± ± 3.5 <0.001 Fertilization/injected oocyte 0 (0/114) 41.6 (96/231) a <0.05 ET cycles 0 (0/31) 82.1 (32/39) <0.05 Embryos transferred (mean) <0.05 Positive bhcg/et (8/32) <0.05 Clinical pregnancy/et (6/32) <0.05 Implantation/embryos transferred (7/57) <0.05 Abortion/clinical pregnancy (1/6) <0.05 Take-home baby/et (5/32) <0.05 Take-home baby/cycle (5/39) <0.05 Values are mean ± SD or % (n/total), unless otherwise indicated. ET = embryo transfer; NS = not significant. a No fertilization occurred in seven patients in seven activation cycles.
4 524 M Montag et al. Table 2 Results of artificial oocyte activation in patients with 1 29% fertilization rates in an initial cycle (group 2). Standard ICSI Artificial oocyte activation P-value Patients (n) Female age (years) 33.3 ± ± 3.7 <0.05 ICSI cycles (n) Oocytes retrieved 8.0 ± ± 4.1 NS Oocytes injected 6.2 ± ± 3.5 NS Fertilization/injected oocyte 19.3 (72/373) 44.4 (161/363) a <0.001 ET cycles (47/47) 87.9 (51/58) <0.05 Embryos transferred (mean) NS Positive bhcg/et 14.9 (7/47) 37.3 (19/51) <0.05 Clinical pregnancy/et 12.8 (6/47) 31.4 (16/51) <0.05 Implantation/embryos transferred 8.6 (6/70) 17.6 (16/91) NS Abortion/clinical pregnancy 0 (0/6) 12.5 (2/16) NS Take-home baby/et 12.8 (6/47) 27.5 (14/51) NS Take-home baby/cycle 12.8 (6/47) 24.1 (14/58) NS Values are mean ± SD or % (n/total), unless otherwise indicated. ET = embryo transfer; NS = not significant. a No fertilization occurred in six patients in seven activation cycles. These patients had only one oocyte fertilized in the previous cycles without activation. Table 3 Results of artificial oocyte activation in patients with 30 50% fertilization rates in an initial cycle (group 3). Standard ICSI Artificial oocyte activation P-value Patients (n) Female age (years) 34.0 ± ± 4.3 NS ICSI cycles (n) Oocytes retrieved 9.2 ± ± 4.7 NS Oocytes injected 7.0 ± ± 3.3 NS Fertilization/injected oocyte 36.8 (64/174) 56.1 (124/221) <0.001 ET cycles 100 (25/25) 90.6 (29/32) NS Embryos transferred (mean) NS Positive bhcg/et 28.0 (7/25) 37.9 (11/29) NS Clinical pregnancy/et 16.0 (4/25) 27.6 (8/29) NS Implantation/embryos transferred 8.7 (4/46) 17.5 (10/57) NS Abortion/clinical pregnancy 50.0 (2/4) 25.0 (2/8) NS Take-home baby/et 8.0 (2/25) 20.7 (6/29) NS Take-home baby/cycle 8.0 (2/25) 18.8 (6/32) NS Values are mean ± SD or % (n/total), unless otherwise indicated. ET = embryo transfer; NS = not significant. were significantly higher following artificial oocyte activation (36.8% versus 56.1%, P < 0.001); however, there was no difference in cycles with embryo transfer (100% versus 90.6%) as well as the mean number of embryos transferred (1.84 versus 1.96). Following artificial activation, positive bhcg rates (28.0% versus 37.9%), clinical pregnancy rates per transfer (16.0% versus 27.6%), implantation rates (8.7% versus 17.5%), abortion rates (50.0% versus 25.0%) and take-home baby rate per transfer (8.0% versus 20.7%) or per ICSI cycle (8.0% versus 18.8%) were in favour of the activation group but did not reach significance due to low numbers. All children born were healthy and no malformations were reported. Discussion Artificial oocyte activation was proposed at the beginning of the ICSI era for improving the overall success rates (Sousa
5 Artificial oocyte activation 525 and Tesarik, 1994). However, with time ICSI proved to be a robust technique with reproducible and comparable results among different clinics (Palermo et al., 1996), especially in view of the fertilization rates. Failure of fertilization after ICSI was initially reported for globozoospermic patients presenting with round-headed spermatozoa (Rybouchkin et al., 1996). The first event in the fertilization cascade is the activation of the oocyte through a sperm-derived oocyte activation factor (Kashir et al., 2010). This factor is considered to be an isoform of phospholipase C, PLCf (Saunders et al., 2002). Several publications report on the absence of PLCf in males with failed fertilization and the majority of these presented with globozoospermia (Heytens et al., 2009; Yoon et al., 2008). Although patients can be tested for the presence or absence of PLCf, other factors may also be involved. This may also comprise activation-related deficiencies in the oocyte or the spermatozoon and changes in the activation cascade which are not yet known as being clinically relevant. The potential of a spermatozoon from a patient to activate oocytes can be investigated by the injection of a spermatozoon or a sperm extract into mouse oocytes and the related mouse oocyte activation test (MOAT) has been used (Rybouchkin et al., 1996). When this test was applied in patients with severe oligoteratozoospermia or with testicular spermatozoa, a high rate of failed oocyte activation was noted (Heytens et al., 2009; Kyono et al., 2008; Tesarik et al., 2002). Although MOAT is a reliable indicator for oocyte activation problems in a subsequent ICSI treatment cycle (Heindryckx et al., 2005), it cannot be applied routinely in every case of fertilization failure or every assisted reproduction unit. Nevertheless, fertilization rates below 50% in repeated ICSI cycles in the same patient can be due to impaired oocyte activation probably caused by a sperm deficiency. This study was conducted on patients who had a first failed ICSI cycle with fertilization rates below 50% and returned for another intervention cycle. The initial failed cycle served as a control. This has implications towards the validity of using such control data for pregnancy rates, as patients achieving pregnancy in a first cycle will probably not return. However, it will not affect activation-induced changes in fertilization rates and hence the patients were grouped according to the fertilization rates in the initial cycles. These data show that oocyte activation has a significant benefit when applied to patients with completely failed fertilization or when fertilization rates were below 30% in the initial ICSI cycle. For the patient cohort with complete fertilization failure in a first cycle, there was an overall change in the stimulation protocol. However, there was not a standard shift from one protocol to another, which would allow for a general statement regarding a possible effect on oocyte activation capacity. These changes probably had an impact on the improvement of the cycle outcome, as more oocytes were available for the subsequent ICSI cycles. However, stimulation protocols were not different in the patient cohort with a fertilization rate of 1 29% in the initial cycle. Subsequent treatment cycles with activation showed no differences for oocyte numbers, and transfer of a comparable mean number of embryos resulted in significantly higher fertilization, biochemical and clinical pregnancy rates. In patients with fertilization rates in the range of 30 50%, there was a significant increase in the fertilization rate but all other investigated parameters did not reach significance. This could be due to the small sample size. However, despite a trend in favour of pregnancy, implantation and take-home baby rates, the success rates for the control group in the 30 50% cohort show that these patients probably did not require activation at all. In view of the activation being another intervention, it is questionable if it should be recommended as a standard treatment in patients with 30 50% fertilization rates. Artificial activation by calcium ionophore causes only a single calcium wave in oocytes and does not lead to calcium oscillations. Therefore, the oocyte still plays a major role in converting this initial calcium peak into an activation-sufficient event. Mimicking calcium oscillations would probably be more critical, as one study showed that a non-physiological oscillation pattern may disturb early embryo development (Ozil et al., 2005). Artificial oocyte activation can overcome the problem of failed (0%) or very low (1 29%) fertilization and it has been also applied by others to patients with normo- or oligozoospermia who otherwise have no underlying disease or other symptoms. These studies showed an improvement in fertilization rates which in some patients even reached normal levels (Heindryckx et al., 2008, 2005; Kyono et al., 2008; Yanagida et al., 2006). As far as is known, the current study is the first to investigate the effect of artificial oocyte activation in relation to the degree of fertilization in the previous ICSI cycle. However, despite the significant increase in fertilization rates, the values reported here do not reach the normal range of more than 70% as reported by others (Heindryckx et al., 2008, 2005) but this may be due to differences in the patient cohort or by the use of an activation protocol which initiates only a single calcium rise instead of calcium oscillations. In the patient cohort of this study, there were no cases of globozoospermia. Therefore reduced fertilization although considered a rare event after ICSI may reveal an aetiology of infertility which still awaits a detailed characterization. This study noted in some treatment cycles in groups 1 and 2 that the application of artificial activation did not improve the results and some patients even received no transfer after activation. However, in these cycles the number of oocytes available for injection was close to 2 3 and thus it is difficult to say if these patients had a real sperm activation deficiency or if the activation procedure failed due to an oocyte problem or the low number of oocytes available. Despite this, it is obvious that if a sperm deficiency is linked to a genetic background, the problem may be passed to the next generation. Hence, artificial oocyte activation needs to be considered as experimental and its application requires thorough consultation with the patient. In conclusion, for patients with 0% or 1 29% fertilization in a standard ICSI cycle artificial oocyte activation may have a beneficial effect in the following treatment cycle. However, these data show that artificial oocyte activation should not be randomly applied and, especially for patients with 30 50% fertilization rates, it may not improve the overall outcome.
6 526 M Montag et al. Acknowledgements The authors acknowledge the expert help of the IVF team at the University Clinics of Bonn. References Battaglia, D.E., Koehler, J.K., Klein, N.A., Tucker, M.J., Failure of oocyte activation after intracytoplasmic sperm injection using round-headed sperm. Fertil. Steril 68, Eldar-Geva, T., Brooks, B., Margalioth, E.J., Zylber-Haran, F., Gal, M., Silber, S.J., Successful pregnancy and delivery after calcium ionophore oocyte activation in a normozoospermic patient with previous repeated failed fertilization after intracytoplasmic sperm injection. Fertil. Steril 79 (Suppl. 3), Heindryckx, B., Van der Elst, J., De Sutter, P., Dhont, M., Treatment option for sperm- or oocyte-related fertilization failure: assisted oocyte activation following diagnostic heterologous ICSI. Hum. Reprod. (Oxford, England) 20, Heindryckx, B., De Gheselle, S., Gerris, J., Dhont, M., De Sutter, P., Efficiency of assisted oocyte activation as a solution for failed intracytoplasmic sperm injection. Reprod. Biomed. Online 17, Heytens, E., Parrington, J., Coward, K., Young, C., Lambrecht, S., Yoon, S.Y., Fissore, R.A., Hamer, R., Deane, C.M., Ruas, M., Grasa, P., Soleimani, R., Cuvelier, C.A., Gerris, J., Dhont, M., Deforce, D., Leybaert, L., De Sutter, P., Reduced amounts and abnormal forms of phospholipase C zeta (PLCzeta) in spermatozoa from infertile men. Hum. Reprod. (Oxford, England) 24, Kashir, J., Heindryckx, B., Jones, C., De Sutter, P., Parrington, J., Coward, K., Oocyte activation, phospholipase C zeta and human infertility. Hum. Reprod. Update 16, Kline, D., Kline, J.T., Repetitive calcium transients and the role of calcium in exocytosis and cell cycle activation in the mouse egg. Dev. Biol. 149, Kyono, K., Kumagai, S., Nishinaka, C., Nakajo, Y., Uto, H., Toya, M., Sugawara, J., Araki, Y., Birth and follow-up of babies born following ICSI using SrCl2 oocyte activation. Reprod. Biomed. Online 17, Liu, J., Nagy, Z., Joris, H., Tournaye, H., Devroey, P., Van Steirteghem, A., Successful fertilization and establishment of pregnancies after intracytoplasmic sperm injection in patients with globozoospermia. Hum. Reprod. (Oxford, England) 10, Montag, M., van der Ven, K., Ved, S., Schmutzler, A., Prietl, G., Krebs, D., Peschka, B., Schwanitz, G., Albers, P., Haidl, G., van der Ven, H., Success of intracytoplasmic sperm injection in couples with male and/or female chromosome aberrations. Hum. Reprod. (Oxford, England) 12, Montag, M., Kupka, M., van der Ven, K., van der Ven, H., Embryo transfer on day 3 using low versus high fluid volume. Eur. J. Obstet. Gynecol. Reprod. Biol. 102, Ozil, J.P., Markoulaki, S., Toth, S., Matson, S., Banrezes, B., Knott, J.G., Schultz, R.M., Huneau, D., Ducibella, T., Egg activation events are regulated by the duration of a sustained [Ca2+] cyt signal in the mouse. Dev. Biol 282, Palermo, G., Joris, H., Devroey, P., Van Steirteghem, A.C., Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet 340, Palermo, G.D., Cohen, J., Rosenwaks, Z., Intracytoplasmic sperm injection: a powerful tool to overcome fertilization failure. Fertil. Steril. 65, Rybouchkin, A., Dozortsev, D., Pelinck, M.J., De Sutter, P., Dhont, M., Analysis of the oocyte activating capacity and chromosomal complement of round-headed human spermatozoa by their injection into mouse oocytes. Hum. Reprod. (Oxford, England) 11, Rybouchkin, A.V., Van der Straeten, F., Quatacker, J., De Sutter, P., Dhont, M., Fertilization and pregnancy after assisted oocyte activation and intracytoplasmic sperm injection in a case of round-headed sperm associated with deficient oocyte activation capacity. Fertil. Steril. 68, Saunders, C.M., Larman, M.G., Parrington, J., Cox, L.J., Royse, J., Blayney, L.M., PLC zeta: a sperm-specific trigger of Ca(2+) oscillations in eggs and embryo development. Development (Cambridge, England) 129, Sousa, M., Tesarik, J., Ultrastructural analysis of fertilization failure after intracytoplasmic sperm injection. Hum. Reprod. (Oxford, England) 9, Swann, K., Ozil, J.P., Dynamics of the calcium signal that triggers mammalian egg activation. Int. Rev. Cytol. 152, Swann, K., Larman, M.G., Saunders, C.M., Lai, F.AA., The cytosolic sperm factor that triggers Ca2+ oscillations and egg activation in mammals is a novel phospholipase C: PLCzeta. Reproduction (Cambridge, England) 127, Taylor, S.L., Yoon, S.Y., Morshedi, M.S., Lacey, D.R., Jellerette, T., Fissore, R.A., Oehninger, S., Complete globozoospermia associated with PLCzeta deficiency treated with calcium ionophore and ICSI results in pregnancy. Reprod. Biomed. Online 20, Tesarik, J., Sousa, M., Mendoza, C., Sperm-induced calcium oscillations of human oocytes show distinct features in oocyte center and periphery. Mol. Reprod. Dev. 41, Tesarik, J., Rienzi, L., Ubaldi, F., Mendoza, C., Greco, E., Use of a modified intracytoplasmic sperm injection technique to overcome sperm-borne and oocyte-borne oocyte activation failures. Fertil. Steril. 78, Yanagida, K., Morozumi, K., Katayose, H., Hayashi, S., Sato, K., Successful pregnancy after ICSI with strontium oocyte activation in low rates of fertilization. Reprod. Biomed. Online 13, Yoon, S.Y., Jellerette, T., Salicioni, A.M., Lee, H.C., Yoo, M.S., Coward, K., Parrington, J., Grow, D., Cibelli, J.B., Visconti, P.E., Mager, J., Fissore, R.A., Human sperm devoid of PLC, zeta 1 fail to induce Ca(2+) release and are unable to initiate the first step of embryo development. J. Clin. Investig 118, Declaration: The authors report no financial or commercial conflicts of interest. Received 12 July 2011; refereed 1 February 2012; accepted 2 February 2012.
Case report Successful pregnancy after ICSI with strontium oocyte activation in low rates of fertilization
RBMOnline - Vol 13 No 6. 2006 801-806 Reproductive BioMedicine Online; www.rbmonline.com/article/2369 on web 19 October 2006 Case report Successful pregnancy after ICSI with strontium oocyte activation
More informationCase report Birth and follow-up of babies born following ICSI using SrCl 2. oocyte activation
RBMOnline - Vol 17 No 1. 2008 53-58 Reproductive BioMedicine Online; www.rbmonline.com/article/3284 on web 19 May 2008 Case report Birth and follow-up of babies born following ICSI using SrCl 2 oocyte
More informationSynchronization between embryo development and endometrium is a contributing factor for rescue ICSI outcome
Reproductive BioMedicine Online (2012) 24, 527 531 www.sciencedirect.com www.rbmonline.com ARTICLE Synchronization between embryo development and endometrium is a contributing factor for rescue ICSI outcome
More informationAbstract. Introduction. Materials and methods. Patients and methods
RBMOnline - Vol 8. No 3. 344-348 Reproductive BioMedicine Online; www.rbmonline.com/article/1178 on web 20 January 2004 Article Cumulative live birth rates after transfer of cryopreserved ICSI embryos
More informationApplication of a ready-to-use calcium ionophore increases rates of fertilization and pregnancy in severe male factor infertility
Application of a ready-to-use calcium ionophore increases rates of fertilization and pregnancy in severe male factor infertility Thomas Ebner, Ph.D., a Maria K oster, Ph.D., b Omar Shebl, M.D., a Marianne
More informationArtificial oocyte activation and intracytoplasmic sperm injection
Artificial oocyte activation and intracytoplasmic sperm injection Mohammad Hossein Nasr-Esfahani, Ph.D., a,b Mohammad Reza Deemeh, M.Sc., a,b and Marziyeh Tavalaee, M.Sc. b a Isfahan Fertility and Infertility
More informationArticle Effect of ionomycin on oocyte activation and embryo development in mouse
RBMOnline - Vol 17. No 6. 2008 764-771 Reproductive BioMedicine Online; www.rbmonline.com/article/3416 on web 21 October 2008 Article Effect of ionomycin on oocyte activation and embryo development in
More informationRole of Ca2+ ionophore in ICSI failed fertilization
Role of Ca2+ ionophore in ICSI failed fertilization Liow Swee Lian DVM, PhD O & G Partners Fertility Centre Gleneagles Hospital SINGAPORE Process of Fertilization Generated by Foxit PDF Creator Foxit Software
More informationReduced fertilization after ICSI and abnormal phospholipase C zeta presence in spermatozoa from the wobbler mouse
Reproductive BioMedicine Online (2010) 21, 742 749 www.sciencedirect.com www.rbmonline.com ARTICLE Reduced fertilization after ICSI and abnormal phospholipase C zeta presence in spermatozoa from the wobbler
More informationCan Assessment of Total Acrosin Activity Help Predict Failed or Low Fertilization Rate ICSI for Implementation of Artificial Oocyte Activation?
The Open Andrology Journal, 2010, 2, 19-26 19 Open Access Can Assessment of Total Acrosin Activity Help Predict Failed or Low Fertilization Rate ICSI for Implementation of Artificial Oocyte Activation?
More informationP.M.M.Kastrop 1, S.M.Weima, R.J.Van Kooij and E.R.Te Velde
Human Reproduction vol.14 no.1 pp.65 69, 1999 Comparison between intracytoplasmic sperm injection and in-vitro fertilization (IVF) with high insemination concentration after total fertilization failure
More informationIranian Journal of Basic Medical Sciences
Iranian Journal of Basic Medical Sciences ijbms.mums.ac.ir Effects of assisted oocyte activation with calcium- ionophore and strontium chloride on in vitro ICSI outcomes Marziyeh Norozi-Hafshejani 1, Marziyeh
More informationIVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW
IVF AND PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) WHAT THE COMMUNITY PHYSICIAN NEEDS TO KNOW Jon Havelock, MD, FRCSC, FACOG Co-Director - PCRM Disclosure No conflict of interest in relation
More informationInterpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used
Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used Ellenbogen A., M.D., Shalom-Paz E., M.D, Asalih N., M.D, Samara
More informationH.Van de Velde 1, Z.P.Nagy, H.Joris, A.De Vos and A.C.Van Steirteghem
Human Reproduction vol.12 no.10 pp.2246 2250, 1997 Effects of different hyaluronidase concentrations and mechanical procedures for cumulus cell removal on the outcome of intracytoplasmic sperm injection
More informationInfluence of sperm immobilization on onset of Ca 2 oscillations after ICSI
Human Reproduction Vol.16, No.1 pp. 148 152, 2001 Influence of sperm immobilization on onset of Ca 2 oscillations after ICSI K.Yanagida 1,3, H.Katayose 1, S.Hirata 2, H.Yazawa 1, S.Hayashi 1 and A.Sato
More informationFailed fertilization after clinical intracytoplasmic sperm injection
Failed fertilization after clinical intracytoplasmic sperm injection Reproductive BioMedicine Online 2009 Vol. 19 No.2. 216 220 Present by R4 郭恬妮 Introduction intracytoplasmic sperm injection (ICSI) choice
More informationFertilization failures and abnormal fertilization after intracytoplasmic sperm injection
Fertilization failures and abnormal fertilization after intracytoplasmic sperm injection Sean P.Flaherty 1, Dianna Payne and Colin D.Matthews Reproductive Medicine Unit, Department of Obstetrics and Gynaecology,
More informationLuteal phase rescue after GnRHa triggering Progesterone and Estradiol
Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective
More informationModified natural cycle IVF and mild IVF: a 10 year Swedish experience
Reproductive BioMedicine Online (2010) 20, 156 162 www.sciencedirect.com www.rbmonline.com ARTICLE Modified natural cycle IVF and mild IVF: a 10 year Swedish experience Arthur Aanesen *, Karl-Gösta Nygren,
More informationArticle Influence of spermatogenic profile and meiotic abnormalities on reproductive outcome of infertile patients
RBMOnline - Vol 10. No 6. 2005 735 739 Reproductive BioMedicine Online; www.rbmonline.com/article/1678 on web 13 April 2005 Article Influence of spermatogenic profile and meiotic abnormalities on reproductive
More informationNumber of oocytes and live births in IVF
Number of oocytes and live births in IVF Dr Sesh K Sunkara MD, MRCOG Royal Marsden Hospital, London Kings Healthcare Partners (Guy s & St Thomas NHS Foundation Trust), London, UK Background IVF results
More informationIVF treatment should not be postponed for patients with high basal FSH concentrations
Reproductive BioMedicine Online (2010) 21, 631 635 www.sciencedirect.com www.rbmonline.com SHORT COMMUNICATION IVF treatment should not be postponed for patients with high basal FSH concentrations Ettie
More informationHonorary Fellow of the Royal College of Obs. & Gyn. First Indian to receive FIGO s Distinguished Merit Award for Services towards women s health.
Prof.Duru Shah Founder President The PCOS Society (India) President Elect of the Indian Society for Assisted Reproduction (ISAR) Honorary Fellow of the Royal College of Obs. & Gyn. First Indian to receive
More informationSpontaneous ovulation versus HCG triggering for timing natural-cycle frozen thawed embryo transfer: a randomized study
Reproductive BioMedicine Online (2011) 23, 484 489 www.sciencedirect.com www.rbmonline.com ARTICLE Spontaneous ovulation versus HCG triggering for timing natural-cycle frozen thawed embryo transfer: a
More informationIntracytoplasmic Sperm Injection Outcome Using Ejaculated Sperm and Retrieved Sperm in Azoospermic Men
Sexual Dysfunction and Infertility Intracytoplasmic Sperm Injection Outcome Using Ejaculated Sperm and Retrieved Sperm in Azoospermic Men Tahira Naru, 1 M Nasir Sulaiman, 2 Atiya Kidwai, 3 M Hammad Ather,
More informationPatient selection criteria for blastocyst culture in IVF/ICSI treatment
J Assist Reprod Genet (2010) 27:555 560 DOI 10.1007/s10815-010-9457-9 ASSISTED REPRODUCTION Patient selection criteria for blastocyst culture in IVF/ICSI treatment M. Y. Thum & V. Wells & H. Abdalla Received:
More informationExtended sperm preparation: an alternative to testicular sperm extraction in non-obstructive azoospermia
Human Reproduction vol.12 no.6 pp.1222 1226, 1997 Extended sperm preparation: an alternative to testicular sperm extraction in non-obstructive azoospermia R.Ron-El 1, D.Strassburger, S.Friedler, D.Komarovski,
More informationIVF: PAST, PRESENT AND FUTURE
IVF: PAST, PRESENT AND FUTURE Mark Larman Chief Scientific Officer 1 HISTORY OF IVF IVF first achieved with rabbits in 1959 IVF with human gametes - pioneered by Robert Edwards and Patrick Steptoe during
More informationI motivi del fallimento nella fecondazione. Laura Rienzi
I motivi del fallimento nella fecondazione Laura Rienzi Fertilization process Cumulus cell penetration Oocyte activation CG reaction completion of meiosis II Sperm/oocyte binding and penetration Sperm
More informationEndometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot study
Reproductive BioMedicine Online (2010) 21, 50 55 www.sciencedirect.com www.rbmonline.com ARTICLE Endometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot
More informationInfertility treatment
In the name of God Infertility treatment Treatment options The optimal treatment is one that provide an acceptable success rate, has minimal risk and is costeffective. The treatment options are: 1- Ovulation
More informationThe association between anti-müllerian hormone and IVF pregnancy outcomes is influenced by age
Reproductive BioMedicine Online (2010) 21, 757 761 www.sciencedirect.com www.rbmonline.com ARTICLE The association between anti-müllerian hormone and IVF pregnancy outcomes is influenced by age Jeff G
More informationMore than 90% fertilization rates after intracytoplasmic sperm injection and artificial induction of oocyte activation with calcium ionophore*
FERTILITY AND STERILITY Copyright c 1995 American Society for Reproductive Medicine Vol. 63, No.2, February 1995 Printed on acid-free paper in U. S. A. More than 90% fertilization rates after intracytoplasmic
More informationMale factors determining the outcome of intracytoplasmic sperm injection with epididymal and testicular spermatozoa
andrologia 35, 220 226 (2003) Accepted: April 25, 2003 Male factors determining the outcome of intracytoplasmic sperm injection with epididymal and testicular spermatozoa J. U. Schwarzer, K. Fiedler, I.
More informationSuccessful pregnancy and childbirth after intracytoplasmic sperm injection with calcium ionophore oocyte activation in a globozoospermic patient
CASE REPORT Successful pregnancy and childbirth after intracytoplasmic sperm injection with calcium ionophore oocyte activation in a globozoospermic patient Alberto Tejera, Ph.D., a Marta Molla, Ph.D.,
More informationInfluence ovarian stimulation on oocyte and embryo quality. Prof.Dr. Bart CJM Fauser
Influence ovarian stimulation on oocyte and embryo quality Prof.Dr. Bart CJM Fauser How to balance too much vs too little? Lecture Outline Context ovarian stimulation Impact ovarian stimulation on oocyte
More informationCryopreservation of human spermatozoa within human or mouse empty zona pellucidae
FERTILITY AND STERILITY VOL. 73, NO. 4, APRIL 2000 Copyright 2000 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Cryopreservation of
More informationIntracytoplasmic Sperm Injection (ICSI) with the Eppendorf micromanipulator TransferMan 4m
APPLICATION NOTE No. 009 I June 2013 Intracytoplasmic Sperm Injection (ICSI) with the Eppendorf micromanipulator TransferMan 4m Verena Nordhoff, Centre of Reproductive Medicine and Andrology, University
More informationCommittee Paper SCAAC(05/09)01. ICSI guidance. Hannah Darby and Rachel Fowler
Committee Paper Committee: Scientific and Clinical Advances Advisory Committee Meeting Date: 12 May 2009 Agenda Item: 4 Paper Number: SCAAC(05/09)01 Paper Title: ICSI guidance Author: Hannah Darby and
More informationMicroinsemination (Intracytoplasmic Sperm Injection) Microinsemination schedule. 1. Preparation of mediums
Microinsemination (Intracytoplasmic Sperm Injection) Masumi Hirabayashi Section of Mammalian Transgenesis, Center for Genetic Analysis of Behavior, National Institute for Physiological Sciences, National
More informationICSI livebirths with globozoospermia
DOI: 10.1111/j.1745-7262.2008.00248.x www.asiaandro.com. Case Report. Clinical pregnancies and livebirths achieved by intracytoplasmic injection of round headed acrosomeless spermatozoa with and without
More informationUnderstanding eggs, sperm and embryos. Marta Jansa Perez Wolfson Fertility Centre
Understanding eggs, sperm and embryos Marta Jansa Perez Wolfson Fertility Centre What does embryology involve? Aims of the embryology laboratory Creation of a large number of embryos and supporting their
More informationINDICATIONS OF IVF/ICSI
PROCESS OF IVF/ICSI INDICATIONS OF IVF/ICSI IVF is most clearly indicated when infertility results from one or more causes having no other effective treatment; Tubal disease. In women with blocked fallopian
More informationCandido Tomás 1,3, Mauri Orava 1, Leena Tuomivaara 2 and Hannu Martikainen 1
Human Reproduction vol.13 no.1 pp. 65 70, 1998 Low pregnancy rate is achieved in patients treated with intracytoplasmic sperm injection due to previous low or failed fertilization in in-vitro fertilization
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Interpreting Follicular Phase Progesterone Ernesto Bosch IVI Valencia,
More informationIntracytoplasmic Sperm Injection (ICSI) with the Eppendorf TransferMan 4m and CellTram 4m
APPLICATION NOTE No. 009 Intracytoplasmic Sperm Injection (ICSI) with the Eppendorf TransferMan 4m and CellTram 4m Verena Nordhoff, Centre of Reproductive Medicine and Andrology, University Hospital of
More informationLaura Rienzi Senior Clinical Embryologist
www.generaroma.it CLINICA VALLE GIULIA, Rome SALUS, Marostica UMBERTIDE, Perugia Laura Rienzi Senior Clinical Embryologist Salzburg, Austria 1,2 April 2011 No commercial activities are related to this
More informationUvA-DARE (Digital Academic Repository) Optimizing the embryo transfer technique Abou-Setta, A.M. Link to publication
UvA-DARE (Digital Academic Repository) Optimizing the embryo transfer technique Abou-Setta, A.M. Link to publication Citation for published version (APA): Abou-Setta, A. M. (2008). Optimizing the embryo
More informationComplete globozoospermia associated with PLCf deficiency treated with calcium ionophore and ICSI results in pregnancy
Reproductive BioMedicine Online (2010) 20, 559 564 www.sciencedirect.com www.rbmonline.com CASE REPORT Complete globozoospermia associated with PLCf deficiency treated with calcium ionophore and ICSI results
More informationA successful pregnancy and live birth after intracytoplasmic sperm injection with globozoospermic sperm and electrical oocyte activation
CASE REPORT A successful pregnancy and live birth after intracytoplasmic sperm injection with globozoospermic sperm and electrical oocyte activation Akiyoshi Egashira, M.S., a Masao Murakami, Ph.D., a
More informationIntracytoplasmic sperm injection (ICSI) for severe semen abnormalities: dissecting the tail of spermatozoa at the tip
Human Reproduction vol 11 no. 12 pp 2640-2644, 1996 Intracytoplasmic sperm injection (ICSI) for severe semen abnormalities: dissecting the tail of spermatozoa at the tip Shee-Uan Chen, Hong-Nerng Ho, Hsin-Fu
More informationNatural Cycle & Mild stimulation IVF/ICSI in women with Poor Ovarian Response (POR)
Natural Cycle & Mild stimulation IVF/ICSI in women with Poor Ovarian Response (POR) Geeta Nargund Head of Reproductive Medicine St George s Hospital London ISMAAR Terminology Human Reprod Nargund et al
More informationFertilization of in vitro matured human oocytes by intracytoplasmic sperm injection (ICSI) using ejaculated and testicular spermatozoa
DOI: 10.1111/j.1745-7262.2005.00016.x. Original Article. Fertilization of in vitro matured human oocytes by intracytoplasmic sperm injection (ICSI) using ejaculated and testicular spermatozoa Yun Qian
More informationOptimize your success
ANDROLOGY BY ORIGIO Optimize your success by selecting the highest quality sperm QUALITY CONTROL OOCYTE RETRIEVAL ANDROLOGY & IUI FERTILIZATION CULTURE PGD & PGS CRYOPRESERVATION EMBRYO TRANSFER The importance
More informationLaser-induced immobilization and plasma membrane permeabilization in human spermatozoa
Human Reproduction vol.15 no.4 pp.846 852, 2000 Laser-induced immobilization and plasma membrane permeabilization in human spermatozoa M.Montag 1,3, K.Rink 2, G.Delacrétaz 2 and sperm plasma membrane (Dozortsev
More informationAcupuncture Treatment For Infertile Women Undergoing Intracytoplasmic Sperm injection
Acupuncture Treatment For Infertile Women Undergoing Intracytoplasmic Sperm injection Sandra L. Emmons, MD Phillip Patton, MD Source: Medical Acupuncture, A Journal For Physicians By Physicians Spring
More informationFertilization rates using intracytoplasmic sperm injection are greater than subzonal insemination but are dependent on prior treatment of sperm
FERTILITY AND STERILITY Vol. 64, No.4, October 199 Copyright (0 199 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A Fertilization rates using intracytoplasmic sperm injection
More informationIntracytoplasmic sperm injection: laboratory set-up and injection procedure
Intracytoplasmic sperm injection: laboratory set-up and injection procedure HJoris 1, Z.Nagy, H.Van de Velde, A.De Vos and A.Van Steirteghem Centre for Reproductive Medicine, Dutch-speaking Brussels Free
More informationIN VITRO FERTILIZATION OF RABBIT EGGS IN OVIDUCT SECRETIONS FROM DIFFERENT DAYS BEFORE AND AFTER OVULATION*
FERTILITY AND STERILITY Copyright~ 1975 The American Fertility Society Vol. 26, No.7, July 1975 Printed in U.SA. IN VITRO FERTILIZATION OF RABBIT EGGS IN OVIDUCT SECRETIONS FROM DIFFERENT DAYS BEFORE AND
More informationASSISTED REPRODUCTIVE TECHNOLOGIES (ART)
ASSISTED REPRODUCTIVE TECHNOLOGIES (ART) Dr. Herve Lucas, MD, PhD, Biologist, Andrologist Dr. Taher Elbarbary, MD Gynecologist-Obstetrician Geneva Foundation for Medical Education and research Definitions
More informationFERTILITY PRESERVATION. Juergen Eisermann, M.D., F.A.C.O.G South Florida Institute for Reproductive Medicine South Miami Florida
FERTILITY PRESERVATION Juergen Eisermann, M.D., F.A.C.O.G South Florida Institute for Reproductive Medicine South Miami Florida 1 2 3 4 Oocyte Cryopreservation Experimental option Offer to single cancer
More informationOUTCOME OF TREATMENT FOR OAT SYNDROME BY INTRACYTOPLASMIC SPERM INJECTION AT THE ART CENTER
OUTCOME OF TREATMENT FOR OAT SYNDROME BY INTRACYTOPLASMIC SPERM INJECTION AT THE ART CENTER Ho Sy Hung, Trinh Thi Thuy Hanoi Medical University, Thaibinh Medical University INTRODUCTION Infertility rate
More informationFertility of ejaculated and testicular megalohead spermatozoa with intracytoplasmic sperm injection
Human Reproduction vol.14 no.3 pp.726 730, 1999 Fertility of ejaculated and testicular megalohead spermatozoa with intracytoplasmic sperm injection S.Kahraman 1,4, C.Akarsu 1, G.Cengiz 1, K.Dirican 1,
More informationMSOME I+II: A NEW CUT-OFF VALUE FOR MALE INFERTILITY AND EMBRYO DEVELOPMENT PREDICTION ON INTRACYTOPLASMIC SPERM INJECTION CYCLES
MSOME I+II: A NEW CUT-OFF VALUE FOR MALE INFERTILITY AND EMBRYO DEVELOPMENT PREDICTION ON INTRACYTOPLASMIC SPERM INJECTION CYCLES Edson Borges Jr 1,2, ; Bianca Ferrarini Zanetti 1,2, Daniela Paes de Almeida
More informationOptimal ICSI timing after the first polar body extrusion in in vitro matured human oocytes
Human Reproduction Vol.22, No.7 pp. 1991 1995, 2007 Advance Access publication on May 18, 2007 doi:10.1093/humrep/dem124 Optimal ICSI timing after the first polar body extrusion in in vitro matured human
More informationPredictive value of embryo grading for embryos with known outcomes
Predictive value of embryo grading for embryos with known outcomes Vanessa N. Weitzman, M.D., Jennifer Schnee-Riesz, M.D., Claudio Benadiva, M.D., John Nulsen, M.D., Linda Siano, M.S., and Donald Maier,
More informationEffects of Cryopreservation on the Ultrastructure of Human Testicular Sperm
Journal of Reproduction & Contraception (2005) 16 (4):195-200 ORIGINAL PAPER Effects of Cryopreservation on the Ultrastructure of Human Testicular Sperm Xin-qiang LAI 1, Wei-jie ZHU 2, Jing LI 3, Fu-xing
More informationRole of embryo morphology in Intracytoplasmic Sperm Injection cycles for prediction of pregnancy
Iranian Journal of Reproductive Medicine Vol.5. No.1. pp:23-27, Winter 2007 Role of embryo morphology in Intracytoplasmic Sperm Injection cycles for prediction of pregnancy Mir Mehrdad Farsi, Ph.D., Ali
More informationBiology of fertility control. Higher Human Biology
Biology of fertility control Higher Human Biology Learning Intention Compare fertile periods in females and males What is infertility? Infertility is the inability of a sexually active, non-contracepting
More informationPatrick Quinn IVF PROTOKOL FOR SINGLE EMBRYO CULTURE
1. With cumulus-free oocytes and embryos up to Day (D) 3, use 275-300 um diameter pipette tips to minimize medium transfer between drops; transfer volume should be < 1 ul. DAY -1 2. At ~ 4.00 pm on the
More informationSpindle examination in unfertilized eggs using the polarization microscope can assist rescue ICSI
Reproductive BioMedicine Online (2013) 26, 280 285 www.sciencedirect.com www.rbmonline.com ARTICLE Spindle examination in unfertilized eggs using the polarization microscope can assist rescue ICSI Jeong
More informationORIGINAL ARTICLE ENDOMETRIAL THICKNESS AND PREGNANCY OUTCOME IN IUI CYCLES
ENDOMETRIAL THICKNESS AND PREGNANCY OUTCOME IN IUI CYCLES Asha Verma 1, Rekha Mulchandani 2, Nupur Lauria 3, Kusum Verma 4, Sunita Himani 5 HOW TO CITE THIS ARTICLE: Asha Verma, Rekha Mulchandani, Nupur
More informationS.Kahraman 1,4, M.Bahçe 2,H.Şamlı 3, N.İmirzalıoğlu 2, K.Yakısn 1, G.Cengiz 1 and E.Dönmez 1
Human Reproduction vol.15 no.9 pp.2003 2007, 2000 Healthy births and ongoing pregnancies obtained by preimplantation genetic diagnosis in patients with advanced maternal age and recurrent implantation
More informationPERCUTANEOUS EPIDIDYMAL SPERM ASPIRATION (PESA) IN MEN WITH OBSTRUCTIVE AZOOSPERMIA
Clinical Urology PESA IN OBSTRUCTIVE AZOOSPERMIA International Braz J Urol Vol. 29 (2): 4-46, March - April, 2003 Official Journal of the Brazilian Society of Urology PERCUTANEOUS EPIDIDYMAL SPERM ASPIRATION
More informationRelationship between human in-vitro fertilization and intracytoplasmic sperm injection and the zona-free hamster egg penetration test
Human Reproduction vol.13 no.7 pp.1928 1932, 1998 Relationship between human in-vitro fertilization and intracytoplasmic sperm injection and the zona-free hamster egg penetration test Hiroaki Shibahara,
More informationShould we advise patients undergoing IVF to start a cycle leading to a day 3 or a day 5 transfer?
Human Reproduction Vol.19, No.11 pp. 2550 2554, 2004 Advance Access publication August 6, 2004 doi:10.1093/humrep/deh447 Should we advise patients undergoing IVF to start a cycle leading to a day 3 or
More informationAbstract. Introduction. RBMOnline - Vol 7. No Reproductive BioMedicine Online; on web 8 July 2003
RBMOnline - Vol 7. No 6. 695-699 Reproductive BioMedicine Online; www.rbmonline.com/article/1008 on web 8 July 2003 Techniques Total quality improvement in the IVF laboratory: choosing indicators of quality
More informationmicromanipulation by vitrolife A complete solution for ICSI procedures.
micromanipulation by vitrolife A complete solution for ICSI procedures. 1 tested, tried and trusted Vitrolife micromanipulation products have been used from the beginning. Used worldwide Vitrolife is the
More informationOriginal Effect of A Time-lapse Incubator (EmbryoScope ) on in vitro Culture of Human Embryos
J. Mamm. Ova Res. Vol. 31 (1), 40 44, 2014 40 Original Effect of A Time-lapse Incubator (EmbryoScope ) on in vitro Culture of Human Embryos Yamato Mizobe*, Toshiaki Akiyoshi, Shiho Minami, Kan Matsuo,
More informationAssisted reproductive technology
Assisted reproductive technology FERTILITY AND STERILITY Copyright 1994 The American Fertility Society Vol. 62, No.4, October 1994 Printed on acid-free paper in U. S. A. Cryopreservation of supernumerary
More informationINTRACYTOPLASMIC SPERM INJECTION
1 Background... 2 2 Male Factor Infertility... 2 3 ICSI... 3 4 Surgical sperm aspiration... 4 5 What is the chance of success?... 6 6 What are the risks?... 7 M Rajkhowa, October 2004 Authorised by V Kay
More informationArticles Cumulative pregnancy rate following IVF and intracytoplasmatic sperm injection with ejaculated and testicular spermatozoa
RBMOnline - Vol 4. No 2. 151 156 Reproductive BioMedicine Online; www.rbmonline.com/article/433 on web 31 January 2002 Articles Cumulative pregnancy rate following IVF and intracytoplasmatic sperm injection
More informationPOST - DOCTORAL FELLOWSHIP PROGRAMME IN REPRODUCTIVE MEDICINE. Anatomy : Male and Female genital tract
POST - DOCTORAL FELLOWSHIP PROGRAMME IN REPRODUCTIVE MEDICINE DURATION OF THE COURSE : TWO YEARS Detailed syllabus: Part 1 Basic Sciences: Anatomy : Male and Female genital tract Physiology Endocrinology
More informationMaking ICSI Safer and More Effective: A Review of the Human Oocyte and ICSI Practice
Review Making ICSI Safer and More Effective: A Review of the Human Oocyte and ICSI Practice MARA SIMOPOULOU 1,2, POLINA GIANNELOU 2, PANAGIOTIS BAKAS 2, LAERTIS GKOLES 2, THEODOROS KALAMPOKAS 2, KONSTANTINOS
More informationMenstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
Human Reproduction Vol.21, No.4 pp. 1012 1017, 2006 Advance Access publication December 8, 2005. doi:10.1093/humrep/dei415 Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
More informationInternational Journal of Technical Research and Applications e Milat Ismail Haje1, Kameel M Naoom2
THE EFFECT OF SPERM PARAMETERS AND BOTH MATERNAL AND PATERNAL AGE ON OUTCOME OF INTRACYTOPLASMIC SPERM INJECTION Milat Ismail Haje 1, Kameel M Naoom 2 1 Postgraduate student in College of Medicine, Hawler
More informationOocyte activation, phospholipase C zeta and human infertility
Human Reproduction Update, Vol.16, No.6 pp. 690 703, 2010 Advanced Access publication on June 23, 2010 doi:10.1093/humupd/dmq018 Oocyte activation, phospholipase C zeta and human infertility J. Kashir
More informationAdoption and Foster Care
GLOSSARY Family building via Adoption and Foster Care October 2018 www.familyequality.org/resources A Anonymous Donor: A person who donated sperm or eggs with the intention of never meeting resulting children.
More informationEnzymatic digestion of testicular tissue may rescue the intracytoplasmic sperm injection cycle in some patients with non-obstructive azoospermia
Human Reproduction vol.13 no.10 pp.2791 2796, 1998 Enzymatic digestion of testicular tissue may rescue the intracytoplasmic sperm injection cycle in some patients with non-obstructive azoospermia E.Crabbé
More informationEasily decapitated spermatozoa defect: a possible cause of unexplained infertility
Human Reproduction vol.4 no. pp.79-795, 999 Easily decapitated spermatozoa defect: a possible cause of unexplained infertility A.Kamal, R.Mansour, I.Fahmy, G.Serour, C.Rhodes and M.Aboulghar,3 The Egyptian
More informationApplication of OMICS technologies on Gamete and Embryo Selection
Application of OMICS technologies on Gamete and Embryo Selection Denny Sakkas, Ph.D. Scientific Director, Boston IVF Waltham, MA, USA THE FUTURE ROLE OF THE EMBRYOLOGIST WILL FOCUS ON PROVIDING OUR PATIENTS
More informationArticle Kinetic markers of human embryo quality using time-lapse recordings of IVF/ICSI-fertilized oocytes
RBMOnline - Vol 17 No 3. 2008 385-391 Reproductive BioMedicine Online; www.rbmonline.com/article/3327 on web 30 July 2008 Article Kinetic markers of human embryo quality using time-lapse recordings of
More informationDirect injection of a single spermatozoon into an oocyte,
Simultaneous removal of sperm plasma membrane and acrosome before intracytoplasmic sperm injection improves oocyte activation embryonic development SEE COMMENTARY Kazuto Morozumi*, Tomohide Shikano, Shunichi
More informationAbstract. Introduction. Materials and methods
RBMOnline - Vol 10. No 5. 2005 645 649 Reproductive BioMedicine Online; www.rbmonline.com/article/1518 on web 18 March 2005 Article Factors predicting IVF treatment outcome: a multivariate analysis of
More informationRejuvenation of Gamete Cells; Past, Present and Future
Rejuvenation of Gamete Cells; Past, Present and Future Denny Sakkas PhD Scientific Director, Boston IVF Waltham, MA, USA Conflict of Interest I have no conflict of interest related to this presentation.
More informationSpermComet DNA Test your results and what they mean
SpermComet DNA Test your results and what they mean Sperm DNA damage and why it is important for your fertility. You and your partner are each going to give some of your DNA to your baby, so the health
More informationQuality Control Processes Within the Embryology Laboratory. Klaus E. Wiemer, PhD Laboratory Director
Quality Control Processes Within the Embryology Laboratory Klaus E. Wiemer, PhD Laboratory Director 8/28/2015 1 Introduction Thorough understanding of every process that occurs within the IVF lab is essential
More informationSherman J.Silber 1,3, Zsolt Nagy 2, Paul Devroey 2, Michel Camus 2 and André C.Van Steirteghem 2
Human Reproduction vol.12 no.12 pp.2693 2700, 1997 The effect of female age and ovarian reserve on pregnancy rate in male infertility: treatment of azoospermia with sperm retrieval and intracytoplasmic
More informationArticles Novel use of laser to assist ICSI for patients with fragile oocytes: a case report
RBMOnline - Vol 4. No 1. 27 31 Reproductive BioMedicine Online; www.rbmonline.com/article/293 on web 15 November 2001 Articles Novel use of laser to assist ICSI for patients with fragile oocytes: a case
More information